ARCHIMED, a healthcare-focused investment firm, has completed its previously announced acquisition of Standard BioTools Inc.'s Microfluidics business. The divested unit will operate as an independent entity named Biomark Scientific under ARCHIMED's ownership. This transaction is part of Standard BioTools' broader strategic consolidation efforts, which also include proposed transactions involving Treeline Biosciences and the sale of its Mass Cytometry business to Element Biosystems. Standard BioTools Inc. develops life science tools and genomic solutions for biomedical research.
